stoxline Quote Chart Rank Option Currency Glossary
Kineta, Inc. (KA)
3.3  0.2 (6.45%)    11-28 13:08
Open: 3.09
High: 3.5
Volume: 13,082
Pre. Close: 3.1
Low: 3.09
Market Cap: 34(M)
Technical analysis
2023-11-28 2:49:30 PM
Short term     
Mid term     
Targets 6-month :  4.91 1-year :  5.72
Resists First :  4.2 Second :  4.9
Pivot price 3.47
Supports First :  3.08 Second :  2.57
MAs MA(5) :  3.15 MA(20) :  3.67
MA(100) :  2.78 MA(250) :  4.35
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  5.9 D(3) :  2.8
RSI RSI(14): 46.4
52-week High :  15.53 Low :  1.77
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ KA ] has closed above bottom band by 38.0%. Bollinger Bands are 50.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 17 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.26 - 3.27 3.27 - 3.29
Low: 3.05 - 3.07 3.07 - 3.09
Close: 3.06 - 3.1 3.1 - 3.13
Company Description

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.

Headline News

Tue, 28 Nov 2023
2023-11-28 | NDAQ:KA | Press Release | Kineta Inc - Stockhouse Publishing

Thu, 09 Nov 2023
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit - Yahoo Finance

Fri, 03 Nov 2023
Kineta Presents New Preclinical Data on Lead Anti-CD27 ... - GlobeNewswire

Fri, 03 Nov 2023
Kineta: Q3 Earnings Snapshot - Chron

Fri, 03 Nov 2023
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Wed, 01 Nov 2023
BCI flourishes despite widespread stock declines - BioWorld Online

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 10 (M)
Shares Float 6 (M)
Held by Insiders 33.2 (%)
Held by Institutions 3.4 (%)
Shares Short 101 (K)
Shares Short P.Month 54 (K)
Stock Financials
EPS -10.54
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.27
Profit Margin 0 %
Operating Margin -330.7 %
Return on Assets (ttm) -141.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.57
EBITDA (p.s.) -1.89
Qtrly Earnings Growth 0 %
Operating Cash Flow -20 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.32
PEG Ratio 0
Price to Book value 12.22
Price to Sales 5.78
Price to Cash Flow -1.75
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2000-01-10
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android